AACHEN, Germany & COPENHAGEN, Denmark--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8; London AIM: PAI) reports that its licensing partner H. Lundbeck A/S today announced the initiation of a clinical Phase III programme with Desmoteplase in the treatment of acute ischemic stroke. The programme consists of two Phase III clinical placebo-controlled trials, each enrolling approximately 320 patients.
